Here is how the global in-vitro diagnostics market is segmented

For those who are unfamiliar, the in-vitro diagnostics market is segmented into Enzyme-Linked Immunosorbent Assay (ELISA), Radioimmunoassay (RIA), Rapid tests, Enzyme-Linked Immunospot (Elispot) Assay and others are some of the immunoassay techniques in the IVD market. Basic Metabolic Panel, Electrolyte Panel, liver Panel, Lipid Profile, Renal Profile and Thyroid function panel and specialty chemical tests are some of the clinical chemistry technologies. Polymerase Chain Reaction (PCR), Isothermal Nucleic Acid Amplification Technology (INAAT), Microarray, Hybridization, DNA Sequencing & Next-Generation Sequencing and others are some of the molecular diagnostics market. Along with these, clinical microbiology, hematology, coagulation and hemostasis and others are the type of the IVD technologies in the market.

According to Research and Markets, among technologies in in-vitro diagnostics market, immunochemistry techniques accounted for the largest share in 2016 growing at mid range single digit CAGR and molecular diagnostics is expected to grow at high single digit CAGR from 2016-2023.

The in-vitro diagnostics global market is a competitive and all the active players in this market are involved in innovating new and advanced products to maintain their market shares.

Among key players in the in-vitro diagnostics global market, we have:

• Abbott Laboratories (U.S.)
• Becton Dickinson (U.S.)
• Bio-Rad laboratories (U.S.)
• BioMerieux (France)
• Danaher Corporation (U.S.)
• Hoffmann-la Roche (Switzerland)
• Siemens AG (Germany)
• Carlyle Group (Ortho Clinical Diagnostics) (U.S.)
• Johnson and Johnson (U.S.)
• Sysmex Corporation (Japan)
• ThermoFisher Scientific (U.S.)
• Hologic Inc (U.S.).